Now That You Can Get What You Want, Can You Keep What You Need?
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Bone and Mineral Research"
DOI: 10.1002/jbmr.3914
Abstract: Combining anabolic therapy, which increases bone formation, with antiresorptive therapies offers hope to increase bone strength and reduce fracture risk more than monotherapy with either type of agent. The study by Cosman and colleagues adds… read more here.
Keywords: fracture; dmab; bmd; study ... See more keywords
Twelve Months of Denosumab and/or Alendronate Is Associated With Improved Bone Fatigue Life, Microarchitecture, and Density in Ovariectomized Cynomolgus Monkeys
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Bone and Mineral Research"
DOI: 10.1002/jbmr.4758
Abstract: Prolonged use of antiresorptives such as the bisphosphonate alendronate (ALN) and the RANKL inhibitor denosumab (DMAb) are associated with rare cases of atypical femoral fracture (AFF). The etiology of AFF is unclear, but it has… read more here.
Keywords: density; fatigue life; bone; dmab ... See more keywords
Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2018 at "Osteoporosis International"
DOI: 10.1007/s00198-018-4492-y
Abstract: SummaryIn biologic-naïve female RA patients, switching oral BPs to DMAb significantly reduced radiographic joint destruction compared to continuing oral BPs or switching to TPTD at 12 months, which were significantly associated with a decrease of a… read more here.
Keywords: radiographic joint; dmab; group; switching oral ... See more keywords
Characterizing patients initiating abaloparatide, teriparatide, or denosumab in a real-world setting: a US linked claims and EMR database analysis
Sign Up to like & getrecommendations! Published in 2020 at "Osteoporosis International"
DOI: 10.1007/s00198-020-05388-y
Abstract: We characterized patients initiating abaloparatide (ABL), teriparatide (TPTD), or denosumab (DMAB) in a real-world clinical setting from a large medical and pharmacy claims database. Differences were noted in sex, age, pathologic fractures, comorbidity index, and… read more here.
Keywords: tptd; dmab; abl tptd; patients initiating ... See more keywords
Monodisperse palladium–cobalt alloy nanocatalyst supported on activated carbon (AC) as highly effective catalyst for the DMAB dehydrocoupling
Sign Up to like & getrecommendations! Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-68773-x
Abstract: In the study, activated carbon (AC) supported palladium/cobalt (Pd/Co) nanocatalyst was synthesized to achieve hydrogen release from dimethylamine boron (DMAB). Nanocatalyst were produced by the reduction of Pd2+ and Co2+ cations by the ultrasonic double… read more here.
Keywords: microscopy; dmab; nanocatalyst; spectroscopy ... See more keywords
Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis
Sign Up to like & getrecommendations! Published in 2020 at "Modern Rheumatology"
DOI: 10.1080/14397595.2020.1769895
Abstract: Abstract Objectives To clarify the effects of follow-on therapy after denosumab (DMAb) discontinuation. Methods In this retrospective, multicenter study, postmenopausal patients with osteoporosis who were previously treated by oral bisphosphonates (BP) (n = 26) or teriparatide (TPTD)… read more here.
Keywords: follow therapy; dmab; effects follow; discontinuation ... See more keywords
Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2017.1263614
Abstract: ABSTRACT Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by focal pathologic bone resorption due to excessive activity of osteoclasts (OC). Receptor activator of nuclear factor kappa B ligand (RANKL) is essential for… read more here.
Keywords: dmab; denosumab targeting; targeting rankl; rheumatoid arthritis ... See more keywords
THU0492 Preliminary study of the bone mass in lung transplanted patients in treatment with denosumab
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.4717
Abstract: Background Osteoporosis(OP) is a known complication before and after a lung transplant. In addition to altering bone mass, treatment with glucocorticoids alters the bone microarchitecture, conditioning an increased risk of fracture in these patients. Denosumab(Dmab)… read more here.
Keywords: treatment dmab; dmab; treatment; bone mass ... See more keywords
OP0298 STUDY OF RISK OF VERTEBRAL FRACTURES AFTER THE WITHDRAWAL OF DENOSUMAB TREATMENT
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.2156
Abstract: Background: The discontinuation of treatment with denosumab (Dmab) has been associated with a reactivation effect of bone metabolism that manifests itself with a loss of bone mass and an increased risk of vertebral fractures (VF).… read more here.
Keywords: treatment; loss; dmab; risk ... See more keywords